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the gap between the basic sciences and clinical application.
Copyright ª 2016, Chongqing Medical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
by-nc-nd/4.0/).Gastroenterology and Hepatology, Department of Medicine, University of Illinois at Chicago, 840 S
IL 60612, USA. Tel.: þ1 312 996 5020.
J. Sun).
f Chongqing Medical University.
016.03.004
ng Medical University. Production and hosting by Elsevier B.V. This is an open access article under the
commons.org/licenses/by-nc-nd/4.0/).
Gut microbiota, inflammation and colorectal cancer 131Introduction
Colorectal cancer is the 3rd most common cancer in both
males and females in the US and the 2nd leading cause of
cancer deaths with the estimated new cases of nearly
133,000 and deaths of 50,000 in 2015.1 Worldwide,
1,360,000 new cases and 694,000 deaths per year are
estimated.2 Cancer incidence in the large intestine is also
known to be approximately 12-fold higher than that of the
small intestine, which has been attributed to several
magnitude greater bacterial density in the large intestine
(w1012 cells per ml) compared with that in the small in-
testine (w102 cells per ml).3 With advance in metagenomic
technology, growing evidence now suggests that dysbiosis,
i.e., imbalance in of normal intestinal microbiota, can
promote chronic inflammatory conditions and the produc-
tion of carcinogenic metabolites, leading to neoplasia.4,5
Gut microbiota represents a complex ecosystem that
develops in close parallel with hosts and depends on the
physiological environment of hosts. Humans have coevolved
with their microbes over thousands of years. The gut bac-
terial population stabilizes during the first years of life and
then remains stable throughout our life in terms of themajor
populations. Human gut microbiota are dominated by four
main phyla: Firmicutes, Bacteroidetes, Actinobacteria, and
Proteobacteria. The corporate number of microbial species
in human gut is estimated to be 1000e1150, with each in-
dividual harboring at least 160 (Qin, Li et al 2010). The
number of genes of gut microbiota exceeds the number of
genes in the human genome by 150 times. A large portion
(38%) of the total gene pool is commonly shared from indi-
vidual to individual. The “core humanmicrobiome” refers to
the central part of microbial gene pool existing in all or most
of humans. The “variable human microbiome” is the mi-
crobial genes in a specific cohort of people, which is
determined by a combination of host factors (Turnbaugh,
Ley et al 2007). In the modern society, the host-microbial
relationship is now being dramatically affected by shifts in
the collective human microbiome resulting from changes in
the environment and societal norms (Sun and Chang 2014).
In this review,wewill discuss the roles of gutmicrobiota in
colorectal cancer, summarizing both epidemiologic observa-
tions and the data from experimental animals. Although
microbiota technically include organisms other than bacteria
e.g., viruses and fungi, this review will primarily focus on
bacteria, of which significant recent progresses have been
made in understanding their role in human health. Specif-
ically, understanding of the interplay between the gut
microbiota, barrier function, and inflammatory responses
will uncover new therapeutic targets in colorectal cancer.We
will discuss thepotential application inprevention,diagnosis,
and therapy of colorectal cancer by targeting gutmicrobiota.
Moreover, we will also discuss challenges lie ahead and the
future direction in studying gutmicrobiome in cancer to close
the gap between the basic sciences and clinical application.
Epidemiological studies of microbiome and
colorectal cancer
At least two approaches have been employed to study
colorectal cancer-associated microbiome. One is thetargeted, more hypothesis-testing studies to examine
whether exposure to specific bacteria species of interest
increases the risk of colorectal cancer. The second type is
studies aiming to identify differences in overall microbial
composition by disease status. The latter has gained more
popularity recently with advances in genomic technology
for high throughput sequencing and discussed here first.
Microbiome core structure, diversity, richness and
colorectal cancer
Most common materials used in these types of investigation
are fecal or mucosal biopsy/resection samples and have
been analyzed primarily by pyrosequencing. But it is now
clear that bacterial populations in feces and mucosa are
distinct.6,7 As summarized in Table 1, the majority of these
studies have demonstrated beta diversity by principal co-
ordinate or component analysis illustrating structural dif-
ference of gut microbiome, where samples belonging to
different disease status (cancer, adenoma, or controls/
normal adjacent tissue) cluster in different two dimensional
spaces,7e12 indicating the presence dysbiosis. Analysis of
community diversity/richness indies based on 16SRNA gene
sequencing has shown significantly reduced microbial di-
versity in feces of colorectal cancer patients than in con-
trols13 and in cancer tissue compared with mucosa at least
10 cm apart from cancer.14 On the contrary a richness index
was higher in rectal mucosa of colorectal cancer patients
than in that of control subjects7 or in cancer tissues than
paired normal tissue.11 Others did not find differences in
these alpha diversity indices.9,10,15,16 With or without using
additional quantitative PCR (qPCR), these studies have also
found that specific bacterial groups were more common or
less common in colorectal cancer cases than control spec-
imens.7e16 Because each study has used different taxonomic
levels/classifications for the comparison, there have little
consistency in changes associated with colorectal cancer.
However, there were multiple studies reporting over-
representation of Fusobacterium and Porphyromonasand
and underrepresentation of Faecalibacterium (Table 1). Yet,
it should be noted that some of these studies were based on
very small numbers of samples and control subjects were
often not comparable with cases in terms of basic de-
mographic factors (such as age). In summary, while these
studies underscore marked differences in gut microbial
membership between colorectal cancer patients and
healthy controls, it is difficult to generalize characteristics
of cancer associated gut microbiome.
Individual bacterial species and colorectal cancer
risk
Streptococcus bovis
Streptococcus bovis (SB) is a gram-positive bacterium and
lower-grade opportunistic pathogen that can cause sys-
temic infections (endocarditis or bacteremia) in humans. It
is a group D streptococcus with the specific ability to grow
in 40 percent bile.17 Intestinal mucosal lesions have been
deemed to serve as a portal for these bacteria to the sys-
temic circulation. Based on biochemical traits, DNA ho-
mology and divergence in 16S rRNA sequences, SB can be
Table 1 Summary of 16rRNA pyrosequencing studies involving colorectal cancer (CRC) and control specimens addressing microbial community structure.
Authors (year) Study subjects (N) Type of specimens 16S rRNA region Beta diversity Alpha diversity Overrepresentation Underrepresentation
Sobhani et al (2011)8 CRC (60), colonoscopy
control (119)
Stool V3eV4 PCA e Bacteroides/
Prevotella
Ahn et al (2013)13 CRC (47), surgical
control (94)
Stool V3eV4 e Shannon index down
in CRC
Fusobacterium,
Porphyromonas
Clostridia
Wang et al (2012)9 CRC (46), healthy
volunteers (56)
Stool V3 PCA No difference in
diversity and
evenness
Porphyromonas,
Escherichia/Shigella,
Enterococcus,
Streptococcus,
Peptostreptococcus
Bacteroides,
Roseburia, Alistipes,
Eubacterium,
Parasutterella
Wu et al (2013)10,65 CRC (19), healthy
volunteers (20)
Stool V3 PCoA No difference in
diversity and richness
Bacteroides species
Fusobacterium
Campylobacter
species
Faecalibacterium,
Roseburia
Weir et al (2013)15 CRC (11), healthy
volunteers (10)
Stool V4 e No difference in
diversity and richness
Akkermansia
muciniphila
Bacteroides,
Prevotella,
Ruminococcus
Chen et al (2012)14 CRC (46), healthy
volunteers (56)
Stool, rectal swab,
cancer tissue,
adjacent (2e5 cm and
10e20 cm apart)
normal mucosa
V1eV3 e Shannon index down
in CRC tissue vs
paired mucosa 10
e20 cm apart
Lactobacillales
(tumor),
Erysipelotrichaceae,
Prevotellaceae,
Coriobacteriaceae
(stool)
Faecalibacterium
(tumor)
Mira-Pascual et al
(2015)7
CRC (7), adenoma
(11), healthy
volunteer (10)
Tissue (tumor or
rectal mucosa), stool
V1eV3 PCoA (tissue) Richness up in cancer
tissue
Enterobacteriaceae
(cancer tissue)
Geng et al (2013)11 CRC (8) Paired tissue (cancer,
normal)
V1eV2 PCoA Richness up in cancer Roseburia Microbacterium,
Anoxybacillus
Geng et al (2014)12 CRC (8), adenoma
(10), healthy
volunteer (10)
Normal and tumor
tissue
V1eV2 PLS-DA e Streptococcus,
Porphyromonas,
Veillonella (cancer vs
control)
Kostic et al (2012)16 CRC (95) Paired tissue (cancer,
normal)
V3eV5 e No difference in
richness
Fusobacterium Bacteroides,
Clostridia,
Faecalibacterium
PCA: Principal component analysis; PCoA: Principal coordinate analysis; PLS-DA; Partial least square discriminant analysis.
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Gut microbiota, inflammation and colorectal cancer 133grouped into Streptococcus gallolyticus (SB biotype I and II/
2) and Streptococcus infantarius (biotype II/1). Earlier
studies suggest stronger association of S. gallolyticus with
colorectal tumors18 in contract to stronger link of S.
infantarius to non-colonic cancers, primarily in the
pancreas and biliary tract.19
Although SB is a member of normal gastrointestinal flora
in ruminants, e.g., cattle, sheep, horses, pigs, camels and
deers, it is also found in human feces as well as gastric biopsy
materials.20,21 Approximately 10% of healthy individuals
have been estimated to carry this bacterium asymptomati-
cally in their digestive tract.20 While fecaleoral or oraleoral
is a possible transmission route between humans, it may be
acquired through dietary intake of ruminant-derived foods,
such as unpasteurized dairy products,22 redmeat and animal
organs.20 In fact SB is a frequently detected contaminant in
commercially available meat.23,24 The correlation between
SB and colonic disease has long been recognized. Besides
case-reports for the patients who were diagnosed with
asymptomatic colorectal neoplasia simultaneously with
SB endocarditis or bacteremia,25e30 investigators have
reported increased prevalence of colorectal tumors (cancer
and polyps) among patients diagnosed with SB endocarditis
or bacteremia. The prevalence of colorectal tumors ranges
from 10 to 60%,18,31e45 although these are based on diverse
study populations in terms of patient demographics and
colorectal surveillance methods. These variations may also
be due to the heterogeneous definition of the cases, as ad-
enomas have been defined as diseased in some studies but
not in the others.46 A more recent study found that 52% of SB
bacteremia patients had advanced adenoma/cancer, which
was approximately 2.5 fold more frequent than colonoscopy
controls.47 Similar prevalence (60%) of advanced adenoma/
cancer was reported in SB endocarditis patients by Sharara
et al.48
The second set of evidence is derived from studies
comparing SB prevalence among various patient groups with
or without colonic diseases.49e56 While 3 small studies
including 13e46 controls and corresponding 11 colorectal
cancer, 47 pediatric inflammatory bowel disease (IBD) and
56 polyp patients failed to show any association,52e54 five
other studies found that SB carriage (either in stool or
antibodies) rates were significantly higher in cancer patients
than in controls. Interestingly, 3 studies also showed that
patients with premalignant lesions (IBD or polyps) had
intermediate SB carriage rate between cancer cases and
controls. In addition, stronger associations observed in
studies by Darjee & Gibb, Tjalsma et al and Abdulamir
et al51,55,56 suggest that antibody assays may be a more
powerful tool than fecal culture in assessing the associations
between this bacterial infection and colorectal disease.
Subsequent enzyme-linked immunosorbent assay (ELISA)
based studies have demonstrated that seropositivity or
higher antibody titer to specific SB antigens or their com-
binations was associated with early stage of colorectal
cancer57,58 or colorectal cancer diagnosed at younger age
(<65 years),59 yielding odds ratios of 1.5e8.0. In summary,
despite these observations it remains elusive whether
colorectal neoplastic sites provide a specific niche for SB
resulting in sustained colonization and survival or whether
SB infection itself promotes colorectal carcinogenesis, or a
combination of both.Helicobacter pylori
H. pylori was designated as a group 1 human carcinogen by
International Agency for Research on Cancer (IARC) in 1994
because an expert panel concluded that there was suffi-
cient evidence in humans for the carcinogenicity of this
bacterial infection and that its chronic infection causes
non-cardia gastric adenocarcinoma and low-grade B-cell
mucosa-associated lymphoid tissue lymphoma.60 H. pylori
is a gastric pathogen that infect more than a half of the
adult population in the world.61 Gastric carcinogenic
pathway caused by H. pylori has been well documented,
arising from stages of premalignant lesions, i.e., chronic
gastritis, atrophic gastritis, intestinal metaplasia and
dysplasia, and then progressing to adenocarcinoma.62e64
While the gold standard for diagnosis of active Heli-
cobacter infection is histological detection in gastric bi-
opsies, stool antigen tests have been clinically accepted as
a non-invasive alternative, indicating H. pylori also resides
in the large intestine. Although no Helicobacter induced
intestinal pathologies have been established, a number of
epidemiologic studies have been conducted to examine if
HP infection increases the risk of colorectal cancer. A
recent meta-analysis by Wu et al65 summarized the data for
3488 colorectal cancer cases, 3792 colorectal adenoma and
10,598 and 4348 corresponding controls from 27 studies.
They reported significantly increased summary odds ratios
for both, 1.39 (1.18e1.64) for cancer and 1.66 (1.39e1.97)
for adenoma. However, two prospective studies66,67 with
the nested caseecontrol design did not find any indication
of increased risk, while all others were either cross-
sectional or retrospective caseecontrol studies. It is note-
worthy that except one study by Jones et al,68 there was no
histological confirmation of presence of H. pylori in colo-
rectal mucosa as others used gastric histology, serology or
breath test to assess H. pylori infection. Nevertheless,
significantly increased risks of cancer and polyps were
observed by Jones et al,68 as well as in an additional study
among children with hamartomous (juvenile) colorectal
polyps,69 respectively. Despite relatively consistent epide-
miologic observations to date, there seems insufficient
evidence to support causality of the events. Certain biases
may be involved, such as publication bias as reported65 as
well as surveillance bias particularly for adenoma. In
addition, there may be indirect consequences from gastric
pathology, such as hypergastrinemia, which is common in
patients with Helicobacter infection and has been hypoth-
esized to stimulate colorectal tumor growth.70
Escherichia coli
Escherichia (E ) coli strains are aero-anaerobic Gram-
negative bacteria in the normal intestinal flora. As a
commensal, E. coli coexist harmoniously with their
mammalian host, promote normal intestinal homeostasis
and rarely cause disease. However, some virulent E. coli
that have acquired pathogenicity islands can colonize the
human gastrointestinal tract and induce disease.71 Mucosa-
associated E. coli have been identified more frequently in
colon tissue from patients with adenocarcinomas than in
controls.72e74 Some E. coli strains harbor a w54-kb poly-
ketide synthases (pks) pathogenicity island that encodes
multi-enzymatic machinery for synthesizing a peptide-
polyketide hybrid genotoxin named Colibactin.75 Carriage
134 J. Sun, I. Katoof E. coli positive to the pks island or genes in the island has
been recently found more common in the mucosa of colo-
rectal cancer and IBD patients than that of control sub-
jects.71,75,76 Epithelial proliferation and E. coli colonization
density were significantly correlated in the mucosa distant
from cancer76 and psk positive cancer specimens showed
higher levels of DNA damage than its negative counter-
parts,77 supporting potential causal link.
Bacteroides fragilis
The anaerobe B. fragilis is a colonic symbiote with an af-
finity for mucosal colonization that comprises a relatively
small proportion of fecal microbiota (approximately 0.5%e
1%). There are 2 molecular subtypes, nontoxigenic B. fra-
gilis (NTBF) and enterotoxigenic B. fragilis (ETBF) and ETBF
is now established as a cause of diarrheal disease.78 ETBF
pathogenicity is due to the B. fragilis toxin (BFT), a 20 kDa
zinc-dependent metalloprotease toxin with 3 isotypes (BFT-
1, BFT-2, and BFT-3) and the bft gene is unique, only
identified in B. fragilis.78 BFT binds to a specific colonic
epithelial receptor activating Wnt and NF-kB signaling
pathways with increased cell proliferation, epithelial
release of proinflammatory mediators, and induction of
DNA damage78,79 and ETBF promotes tumor formation in
experimental animals.79,80 Despite these laboratory data,
to date only limited data in humans support an association
of ETBF with colorectal cancer. Ulger Toprak et al81 re-
ported that 38% of fecal samples from cancer patients were
positive to btf gene while only 12% of those from control
patients were positive (P Z 0.009). Boleij et al82 recently
revealed more frequent detection (w75%) of btf genes in
colonoscopic biopsies, particularly among patients with no
antibiotic pretreatment and the prevalence was signifi-
cantly higher in cancer than controls.
Fusobacterium (F ) nucleatum
F. nucleatum is a Gram negative, non-spore forming, obli-
gate anaerobic of the Fusobacteriaceae family, which
consists of 9 genera, including Fusobacterium and
Leptotrichia. Fusobacterium genus includes at least 14
species, several of which (including F. nucleatum) are
known pathogens.83 F. nucleatum is perhaps best appreci-
ated for its role as a component of oral plaque, where by
virtue of its adhesive abilities it serves as a bridge organism
between early and late colonizers of this biofilm and
consequently is implicated in various forms of periodontal
diseases.84
Until recently, F. nucleatum was thought to primarily be
a component of the oral microbiota of humans and only an
occasional resident of the gut. However, this premise was
built on culture-based examination of stool, which usually
does not contain high numbers of live, epithelium-
associated bacteria. Using metagenomic approaches
recently, growing number of studies have reported an over-
representation of sequences from F. nucleatum16,85,86 or
genus F5,87,88 in tumors relative to control specimens. Two
of these by Castellarin86 and by Warren87 were based on
RNA, representing transcribing bacteria. These observa-
tions were further confirmed by quantitative (q) PCR and in
situ hybridization in tumor tissue.16,86,89 Using qPCR, McCoy
et al studied F counts in normal rectal mucosa of the cases
with or without colorectal adenoma, revealing a 3 foldincrease in risk of adenoma among subjects with highest
tertile of F counts.90 Ito et al91 also demonstrated that F.
nucleatum detection in formalin-fixed paraffin-embedded
tissue by qPCR progressively increased with malignant
grades of the lesions from hyperplastic polyps to colorectal
cancer. Several others found higher fecal carriage of genus
F13,85,92 or Fusobacteriaceae family10 in colorectal cancer
patients than in control subjects, pointing to a potential
tool for colorectal cancer screening.
All F. nucleatum strains may not equal in their virulence
potential. F. nucleatum is naturally co-aggregative and
would likely exist in the human gut microbiota as a feature
of a larger microbial grouping. The ability to adhere to
other bacterial species could also enable gene transfer and
thus some F. nucleatum strains may acquire genes through
horizontal transfer leading to increased virulence,93 which
suggests that the involvement of F. nucleatum in disease
may not be just a function of a direct result of its own
virulence. Despite these accumulated evidences, however,
whether this association is indeed involved in colorectal
carcinogenesis, or simply the result of F. nucleatum
exploitation of an ecological niche created as a result of
the cancer/tumor microenvironment, remains to be tested
in further studies.
Salmonella enterica
S. enterica is a Gram-negative, facultative anaerobe and an
intracellular pathogen to both humans and animals, posing
a major public health concern worldwide. Non-typhoidal
Salmonella is a major foodborne pathogen, with an esti-
mated 93.8 million cases and about 155,000 deaths globally
per year.94a Common sources of infection include contam-
inated food, such as meat, eggs and produce.94b Outcomes
of this bacterial infection vary widely, ranging from mild
self-limiting gastroenteritis to the severe systemic infection
that can be fatal. Some of these acute infections result in a
chronic carrier state excreting the bacteria in stool and
urine without symptoms, which represents another trans-
mission mechanism of this bacterium to other humans.
Salmonellosis has also been implicated in the development
of various chronic sequelae, including reactive arthritis,
irritable bowel syndrome, IBD95 and even cancer.96
Two studies from Scandinavian countries have found that
the probability of new IBD diagnosis significantly (2e3 fold)
increases compared with general population following an
episode of non-typhoid salmonella infection, particularly
within the first 10 years.97,98 Although data directly linking
to colorectal cancer are still limited, Salmonella typhi
carries status is well recognized to increase the risk of
gallbladder cancer. A meta-analysis by Nagaraja et al
demonstrated the summary odds ratio of 3e496 regardless
of salmonella detection methods. Furthermore, Kato et al99
recently reported that antibody against Salmonella flagellin
was higher in colorectal cancer and pre-cancer cases than
controls in two distinct populations in US and the
Netherlands and that dietary intake is the one of the
mediating factors, supporting a possible link of Salmonella
to colorectal cancer.
Other miscellaneous
Several other species of bacteria have received research
interest because their bacterial metabolites have potential
Gut microbiota, inflammation and colorectal cancer 135detrimental effects against colorectal mucosa or may exert
potentially beneficial or protective effect towards epithelial
cells. These include Desulfovibrio, Enterococcus faecalis
due to hydrogen sulfide and superoxide respectively,100
Faecalibacterium prausnitzii and Bifidobacteria due to
butyrate and lactate, respectively.101,102 The presence or
density/quantity of these bacteria in feces or mucosa has
been primarily studied by qPCR. However, there have been
only sporadic studies reporting a significant association with
colorectal cancer itself,101,102 while others found higher
prevalence or density of these bacteria in IBD than in
controls, which was further correlated with disease activ-
ity.4,103,104 In addition to F. nucleatum, Porphyromonas
gingivalis, another oral pathogen more tightly associated
with periodontal disease has been linked to digestive tract
cancer in a seroepidemiologic study. However, the study was
too small to separate colorectal cancer from other
cancers.105 The potential association of this bacterium with
colorectal cancer may be further corroborated by several
other metagenomic studies that observed the
overrepresentation of genus Porphyromonas or
Porphyromonadaceae family in colorectal cancer specimens
than control specimens.10,13,92 Overall, the information
available thus far for these bacteria is insufficient to address
their etiological involvement in colorectal cancer.Interactions between colorectal cancer risk factors
and gut microbiome
As discussed above, growing evidence now point to differ-
ential gut microbial compositions or differential prevalence
of specific bacteria in colorectal cancer patients in com-
parison with control subjects. However, there are also
abundant data supporting the associations between gut
microbiota and several established risk factors for colo-
rectal cancer. Thus, one should consider a possibility that
observed difference in microbiota mirror at least in part
changes associated with such risk factors. The best example
is obesity. Obese and lean individuals are known to harbor
different types of gut microbiota.106 While low energy diet
induces change in microbial compositions increasing gene
richness,107 microbiome itself also contributes energy har-
vest to the host, as demonstrated in mice models where
transfer of obese microbiome to lean animals led to an
increase in body adiposity in a diet dependent
manner.108,109 Other dietary risk factors for colorectal
cancer include low fiber and high red meat intake.110 Di-
etary fiber and resistant starch are well known to stimulate
gut bacterial fermentation to generate short chain fatty
acids (SCFA) as well as lactate and to increase relative
abundance of bacterial groups with the relevant metabolic
activities.111 Although meat intake itself has been rarely
studied, removal of animal products (vegan diet) was
recently tested in a few clinical trials, showing changes in
the Firmicutes/Bacteroidetes ratio and abundance of bac-
teria capable of triggering inflammation.112,113 Moreover, as
discussed above, meats are one of the suspected sources of
acquisition of specific pathogens, e.g., S. Bovis ad Salmo-
nella enterica. There has been relatively sparse informa-
tion as to the associations between other risk factors,
physical activity, smoking and alcohol, and gut microbiome.A study from Ireland found that athletes hard significantly
higher microbial diversity than controls.114 Alcoholics have
been reported to carry greater abundance of Proteobac-
teria or its family Enterobacteriaceae115,116 than control
subjects. Smoking cessation led to changes in gut microbial
composition, increasing some Firmicutes and decreasing
some Bacteroidetes and Proteobacteria,117,118 while Kato
et al demonstrated a positive association between smoking
and Desulfovibrio abundance.119 Since these risks factors
are postulated to be involved in multiple mechanistic
pathways, contribution of microbial changes to colorectal
carcinogenesis remains to be determined.
Cautions in the interpretation of epidemiologic
data
Despite the presence of certain biological mechanisms
possibly contributing to colorectal carcinogenesis (dis-
cussed in later sections), the causal association cannot be
inferred only from the data from retrospective or cross-
sectional human studies. Except a few for H. pylori66,67 and
P. gingivalis,105 all other studies identified the exposure,
i.e., the presence bacteria or their antibodies to bacteria,
was assessed at or after diagnosis of the disease. This
makes it difficult to establish the temporal sequence of the
events, which came first, bacteria or cancer. Moreover, the
presence of the organism may no longer necessary once
carcinogenic pathways are activated by infection as seen in
the case of HP and gastric cancer. Serum antibody assays
can capture past and current infection and have played a
vital role in establishing infectious etiology of several types
of cancer, including H. pylori and hepatitis viruses,120
especially with use of prediagnostic blood samples from
prospective cohorts. Thus, development of reliable sero-
logical assays is likely to greatly advance epidemiologic
studies. However, due to the limitation of serology as well
as fecal analyses, i.e., an inability to identify the location
of colonization for the bacteria that can colonize at diverse
anatomical sites, histological detection of bacteria in can-
cer and surrounding tissues would also be required to
reinforce their causal involvement.
Mechanisms for microbially induced/promoted
colorectal cancer
A systemic review summarizes the original articles studying
microbiota and colorectal cancer until November 2014. It
showed that some bacteria are consistently augmented
(such as Fusobacteria, Alistipes, Porphyromonadaceae,
Coriobacteridae, Staphylococcaceae, Akkermansia spp. and
Methanobacteriales), while other are constantly diminished
in colorectal cancer (such as Bifidobacterium, Lactoba-
cillus, Ruminococcus, Faecalibacterium spp., Roseburia,
and Treponema). It is clear that bacteria metabolites amino
acids are increased and butyrate is decreased throughout
colonic carcinogenesis.121
Identification of components of the microbiota and
elucidation of the molecular mechanisms of their action in
inducing pathological changes or exerting beneficial activ-
ities could aid in our ability to influence the composition of
the microbiota and to find bacterial strains and components
136 J. Sun, I. Kato(e.g., probiotics and prebiotics) whose administration may
aid in disease prevention and treatment.122
Experimental animal models to study microbiome
in colon cancer
To study the microbiome in colon cancer, researchers have
developed various Experimental animal models: gnotobio-
logical model, antibiotic treatment, inflammatory model
with increased risk of colon cancer, inoculation of specific
bacteria or products in genetic engineering mice.
Gnotobiological model is an indispensable tool for
studying the consequences of bacterial colonization. Ani-
mals (such as zebrafish, mouse, rat, pig) can be maintained
in sterile conditions and colonized with defined microbes.
The effects of the germ-free state or the effects of colo-
nization on disease initiation and maintenance can be
observed in these experimental models for disease initia-
tion and progression. Using this approach, researchers have
demonstrated direct involvement of components of the
microbiota (including non-cultivable commensal bacteria)
in chronic intestinal inflammation, development of colonic
neoplasia, and other diseases.
A variety of bacterial species and tumor-promoting
virulence mechanisms have been investigated, using mouse
models. There involve bacterial metabolic products, Path-
ogenic bacterial toxins/virulence factors, and Immune re-
action/modulation.
Bacterial metabolic products
Firmicutes and Bacteroidetes predominate the gut micro-
biota, followed by Proteobacteria and Actinobacteria, with
minor contributors including Verrucomicrobia and Fuso-
bacteria.123 Bacteroides and Ruminococcus are consistent
with enriched intake of animal sources, while a plant-based
diet favors Prevotella.124 Prevotella to Bacteroides ratio
constitutes an important index for clinical diagnosis.
Butyrate-producing bacteria, including Clostridium groups
IV (Faecalibacterium prausnitzii) and XIVa, Roseburia spp.,
Butyricicoccus, and lactic acid bacteria (LAB), mainly
Lactobacillus and Bifidobacterium, are believed to benefit
the host through anti-inflammation, anti-tumorigenesis,
and pathogen exclusion.125e127 There is also a metabolic
interplay between LAB and butyrate-producing bacteria
due to the ability of the latter to feed on lactate.128
It is known that gut microbiota could produce an enor-
mous quantity of molecules interacting with the host. The
beneficial effects of gut microbiota on the host are mainly
mediated by its metabolites. Short-chain fatty acid (SCFA),
including acetate, propionate, and butyrate, are the major
end-products of gut bacteria fermentation of dietary fiber.
SCFAs, particularly butyrate, are the preferred source of
energy for colonic epithelial cells. SCFA promotes and
maintains colonic epithelial health through maintaining
barrier function,129 suppressing colonic cancer,130e132
inhibiting intestinal inflammation (Wu et al 2014), modu-
lating immune response,133 regulating DNA methylation for
proliferation,132 and diminishing oxidative DNA damage.134
The balance between two phyla (Firmicutes and Bac-
teroidetes) appears to be critical to regulating diseaseprogression. Some bacterial species have been implicated
in the development of colorectal carcinoma. Using culture
methods, Moore and Moore observed that the abundance of
Bacteroides and bifidobacteria was associated with
increased risk of colon polyps, whereas Lactobacillus and
Eubacterium aerofaciens were protective.135 An associa-
tion between the abundance of Fusobacterium, E. coli,
hydrogen sulfide (H2S)-, and bile salt-producing bacteria
was associated with increased risk of colon cancer.5,136
Cancer is associated with reduced abundances of Clos-
tridium, Roseburia, Eubacteria spp., and other butyrate-
producing bacteria in fecal samples of adenoma subjects
compared with healthy controls. Zeller et al85 reported that
a relative abundances of 22 gut microbial species, such as
Fusobacterium collectively associated with CRC. This is the
first paper based on the whole sequence of bacterial genes,
not 16S. It also compared the bacterial markers with the
results of the standard Hemoccult FOBT routinely applied
for CRC screening and an experimental CRC screening test
based on methylation of the wif-1 gene, a Wnt pathway
member. The authors believe that there is a potential to
use fecal microbiota markers for early-stage detection of
colorectal cancer.Pathogenic bacterial toxins/virulence factors
Salmonella infection in humans can become chronic which
leads to low grade persistent inflammation.137 These
chronic infections increase the risk of several gastrointes-
tinal138 diseases, including chronic cholecystitis and gall-
bladder cancer.139,140 Recently, Kato et al reported that
antibody against Salmonella flagellin was higher in colo-
rectal cancer and pre-cancer cases than controls in two
distinct populations in US and the Netherlands and that
dietary intake is the one of the mediating factors, sug-
gesting a potential link of Salmonella to colorectal can-
cer.99 In animal models, Salmonella and its derivatives have
been observed invading transformed tissue more efficiently
than normal tissue.141,142 Salmonella AvrA is a multifunc-
tional protein that influences eukaryotic cell pathways by
altering ubiquitination and acetylation of target
proteins.143e149 We reported that AvrA acts as a deubiqui-
tinase to stabilize b-catenin. By suppressing b-catenin
degradation, AvrA enhances intestinal epithelial prolifera-
tion, thus promoting tumorigenesis.150 We reported that
AvrA-enhanced tumor multiplicity and tumor progression.
Our studies could suggest biomarkers (such as AvrA level in
gut) to assess cancer risk in susceptible individuals and
infection-related dysregulation of b-catenin signaling in
colon cancer. Another novel finding in our study was that
the pathogenicity factor altered tumor distribution. Unin-
fected mice treated with AOM/DSS developed tumors in the
distal colon.150 In contrast, in mice infected with AvrA-
expressing bacteria, tumors were found more in the prox-
imal colon. AvrA alters the colonic milieu so as to enhance
tumorigenesis in the right colon. Compared with the left
colon, the cecum has a greater bacterial load and increased
bacterial fermentation that we speculate contributes to
this rightward shift in tumors. Increasing incidence in right-
sided tumors has also been reported in the Western world.
While increased endoscopic screening that probably clears
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colonic lesions, based on our studies, this shift might also
reflect changes in the microbiome. However, it remains
unclear how many human CRC cases can be attributed to
bacterial agents, how these exactly interact with the
human host or the microbial community in the gut.
Gut microbiota metabolism could be linked with polyp
formation, using mice genetic model.151 A diet reduced in
carbohydrates resulted in reduced polyp formation in
APCMin/þ MSH2/ mice. Butyrate, a bacterial product,
induced aberrant proliferation and transformation of colon
epithelial cells. Treatment with either antibiotics or a low-
carbohydrate diet reduced cell proliferation as well as the
number of tumors in the small intestines and colons.
However as mice microbial ecology is different, compared
to human, authors did not found Fusobacterium, which was
shown to be link to CRC in humans.
A paper from Journal of Experimental Medicine152 re-
ported that antibiotics prevented polyp formation. Most of
the tumor-dwelling bacteria belonged to the Clostridiales
family and an upregulation of inflammatory molecules near
the polyps. FMT from the untreated mice to the once germ-
free mice, the previous germ-free mice developed polyps.
If transplanted early embryos of the transgenic mice into
females of another, cancer-free mouse strain. Inoculated at
birth with the bacteria of their surrogate mothers, these
transplanted mice did not develop tumors until 25 weeks,
whereas the genetically identical controls had tumors by 12
weeks. This showed that small changes in the gut micro-
biota could have a large influence on tumor growth. This
study indicates that the same genetic mutation in different
individuals may have a different outcome.152
One environmental factor e a diet low in fiber e may
impact the intestinal microbiota in a way that affects host
cell physiology, cellular homeostasis, energy regulation,
and/or metabolism of xenobiotics. This in turn may lead to
chronic inflammation and CRC. Cancer is associated with
reduced abundances of some butyrate-producing species.
Transplanting feces from mice with CRC into germ-free
mice leads to increased tumorigenesis.153
While emerging evidence suggests a link between the
gut microbiota and colon cancer, it is hard to say that
certain bacteria strain(s) play a causal role in CRC. Evi-
dence is still needed to determine whether those bacteria
enhance the development of the disease or might even play
a causal role.
Cancer is fueled by deregulation of signaling pathways in
control of cellular growth and proliferation. These path-
ways are also targeted by infectious pathogens en route to
establishing infection. It is established that a single infec-
tious agent, namely H. pylori, hepatitis B virus, plays a
causal role in human gastric and hepatic cancers, respec-
tively. The exact roles and mechanisms of microbes on the
development of colon cancer in are still unknown and of
great interests.Immune reaction/modulation
Although genes contribute to colorectal cancer (CRC), the
gut microbiota are an important player. Accumulating evi-
dence suggests that chronic infection and the ensuinginflammation contributes to tumor initiation and tumor
progression.137,154 A variety of bacterial species and tumor-
promoting virulence mechanisms have been investigated,
using mouse models. A recent study in mice showed that
adenomas cause barrier defects in the colonic epithelium
allowing microbial products to drive IL-23/IL-17-mediated
tumor growth.155 Another study demonstrated that a
human colonic commensal bacterium promoted tumori-
genesis via activation of T helper type 17 T cell responses.80
Colitis was shown to promote tumorigenesis by altering
microbial composition and inducing the expansion of mi-
croorganisms with genotoxic capabilities.75 Arthur et al
reported the intestinal microbiota as a target of inflam-
mation that affects the progression of CRC. Monocoloniza-
tion with the commensal E. coli NC101 promoted invasive
carcinoma in azoxymethane (AOM)etreated Il10/ mice.
Specifically, deletion of the polypetide synthase genotoxin
from E. coli NC101 decreased tumor load and tumor inva-
sion in AOM treated IL10 knockout mice. E. coli NC101
mutant without the polyketide synthase (pks) genotoxic
island decreased tumor multiplicity and invasion in AOM/
Il10/ mice. Mucosa-associated pksþ E. coli were found
in a significantly high percentage of inflammatory bowel
disease and CRC patients. These studies have highlighted
the essential roles of bacteria and/or their products in
colonic tumorigenesis.
SCFA is known to modulate immune responses in intes-
tine.133 Another bacterial product Peptidoglycan (PTGN)
modulates peripheral immune function via a pattern-
recognition receptor, oligomerization domain-containing
protein-1 (NOD1) and depletion of the microbiota in
mice.133 Lower systemic PTGN concentration leads to less
ability to kill certain bacterial pathogens. Polysaccharide A,
produced by a commensal bacteria, increases local inter-
leukin 10 by inducing Foxp3þ regulatory T-cell and this
effect is mediated by Toll like receptor 2 signaling.156,157
Although recent studies provide insights into the roles of
the bacterial products, the molecular mechanisms of the
beneficial effects are not fully elucidated yet.
Analysis of the functions that significantly differed be-
tween healthy participants and cancer patients revealed a
global metabolic shift from predominant utilization of di-
etary fiber in the tumor-free colon to more host-derived
energy sources in CRC.85 They hypothesize that an
increased degradation of host glycans might be related to
the etiology of CRC. In healthy gut metagenomes, exclu-
sively some fiber-degrading enzymes and fiber-binding do-
mains are enriched, whereas in CRC metagenomes, the
microbiota appeares to exploit growth substrates derived
from host cells to a much larger extent.85
In summary, the general mechanisms for bacteria e
associated (or induced) GI tumorigenesis are through
enhancing toxic bacterial products, decreasing beneficial
bacterial metabolites, disrupted tissue barriers. Abnormal
immunity, chronic inflammation, and hyperpreliferation
also contribute to the progression of cancer (Fig. 1). Mi-
crobial pathogens and intestinal inflammation can
compromise intestinal barrier function and result in
increased gut permeability, translocation of various mi-
crobial substances, and immune activation.158a Dysbiosis
further enhances barrier failure and inflammation. The host
factor, such as genetic defect, could enhance the dysbiosis
Host 
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Chronic
Inflammation
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Microbial
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Fig. 1 Working models of general mechanisms for bacteria e associated (or induced) colon cancer. Through enhancing toxic
bacterial products, decreasing beneficial bacterial metabolites, disrupted tissue barriers, translocation of microbes, dysbiosis leads
to abnormal immune activation, chronic inflammation, and hyperpreliferation that contribute to the colorectal cancer. The host
factor, such as genetic defect, could enhance the dysbiosis along with the environment trigger and change of dietary.
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(Fig.1). One unanswered question is how microbes affect
the intestinal epithelium: Do the bacteria make it more
permeable or just capitalize on its pre-existing weak spots?Target gut microbiota in prevention diagnosis,
and therapy of GI cancers
Based on current understandings of the roles of microbiota
in GI cancer, targeting the gut microbiota is a promising
avenue in order to prevent cancer or at least stop the in-
crease of cancerous cells. O’Keefe et al158b investigated the
role of fat and fiber in this association by conducting 2-
week-long food changes in volunteers from both pop-
ulations: African-Americans received an African-style diet
high in fiber and low in fat, while rural Africans received a
high-fat, low-fiber ‘Western’ diet. They found the food
changes led to remarkable reciprocal changes in mucosal
biomarkers of cancer risk. The dietary switch also changed
the microbiota and metabolism in ways known to affect
cancer risk.158b This study suggests the potential of dietary
intervention or use of prebiotics in colorectal cancer
prevention.
Insights into microbiome and cancer risk also provide the
opportunities to use of fecal microbial detection for mass
screening and diagnosis. By comparing the fecal CRC data
to those of IBD patients the researchers could confirm that
the microbial characteristics found in the feces were really
specific to CRC and not just indicative of inflammatory in-
testinal conditions in general. The use of fecal microbial
CRC detection for mass screening will depend on the
development of procedures that are more cost-effective
than the ones we used for research purposes.85
The idea of using bacteria as a potent cancer fighting
therapy traces its roots back to the early nineteenthcentury, when French researchers first noticed that bac-
terial infections in people with cancer often led to
shrinkage of their tumors. Increasing evidence has demon-
strated that targeting microbiome can improve therapy
effects of anti-cancer drugs. Wallace et al reported that
inhibiting an enzyme beta-glucuronidase produced by gut
microbiota can improve cancer therapy by preventing the
intestinal metabolism of the anticancer drug irinotecan.159
More studies have also shown that gut microbes make three
anticancer therapies most effective.160a Melanoma growth
in mice harboring distinct commensal microbiota and
observed differences in spontaneous antitumor immunity,
which were eliminated upon cohousing or following fecal
transfer. Bifidobacterium is identified to be associated with
the antitumor effects. Oral administration of Bifidobacte-
rium promotes antitumor immunity and facilitates anti-PD-
L1 efficacy (checkpoint blockade).160b This study also in-
dicates the importance of gut microbiota in other cancers
beyond the GI cancer. Although different bacterial groups
are implicated in enhancing cancer therapy, the same
endpoint through different drugs and different bugs further
indicate the novel role of gut microbiome in health and
diseases.
Cachexia is a multifactorial condition characterized by
systemic inflammation and severe wasting of skeletal
muscle, with or without wasting of adipose tissue that
causes considerable morbidity and mortality in cancer pa-
tients. Infections and inflammation can lead to cachexia
and wasting of skeletal muscle and fat tissue by as yet
poorly understood mechanisms. Gut colonization by a strain
of E. coli prevents wasting triggered by infections or
physical damage to the intestine.161 During intestinal
infection with Salmonella Typhimurium or pneumonic
infection with Burkholderia thailandensis, the presence of
this E. coli did not alter changes in host metabolism, caloric
uptake, or inflammation but instead sustained signaling of
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kinase/AKT pathway in skeletal muscle, which is required
for prevention of muscle wasting. This effect was depen-
dent on engagement of the NLRC4 inflammasome.161
Therefore, commensal bacteria in gut promote tolerance
to diverse diseases.
Compromised gut barrier function because of dysbiosis
or intestinal inflammation can lead to translocation of mi-
crobial substances and the development of systemic
inflammation with potential consequences for patients
prone to cachexia. A recent study showed that non
digestible oligosaccharides modulate the gut microbiota
may constitute a new nutritional strategy to modulate gut
microbiota with positive consequences on cancer progres-
sion and associated cachexia.162 Research is needed to
clarify the role of gut microbiota and systemic inflamma-
tion in the cause of cancer cachexia. Efforts to preserve the
integrity of the gut epithelial barrier and/or limit intestinal
inflammation in cancer patients may help avoid the serious
metabolic alterations associated with cachexia. Multimodal
treatment strategies that include interventions aimed at
maintaining gut barrier function and correcting dysbiosis
may be used to in controlling cachexia.
Microbiota-based cancer prevention, diagnosis, and
therapy are beginning to emerge as researchers learn to
‘decode’ the meaning of human microbiota composition at
different stages in cancer.
Conclusion and future direction
Growing evidence suggests that human microbiota play
novel roles in the progression of colon cancer. The advance
of current experimental models and methods allow us to
obtain the scientific understanding of the interplay be-
tween the gut microbiota, barrier function, and host re-
sponses. These insights will leads to uncover new
therapeutic targets in cancer. Despite these gains, many
challenges lie ahead that make it difficult to close the gap
between the basic sciences and clinical application.
We believe the following steps are needed in order to
move the current microbiota research into clinical practice.
First, we need focus on gaining mechanistic insights.
Microbiota functions will be important to be considered. We
already generated huge information from microbiota ana-
lyses. Based on the genomic analyses, we need analyze the
microbiota of individuals. Second, we need simple and low-
cost tools to identify key bacteria in patients with colon
cancer. For GI patients who will undergo therapy e surgery,
chemotherapy e we should follow-up of these bacteria and
try to understand why some of those will have very good
response to therapy and some others will not. Last, iden-
tification of components of the microbiota and elucidation
of the mechanisms of their action in inducing pathological
changes or exerting beneficial, disease-protective activities
could aid in our ability to influence the composition of the
microbiota. Understanding gut microbiota in cancer will
open a door for the prevention, diagnosis and therapy.
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